ReviewEcancermedicalscience2015
Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake.
Review in Ecancermedicalscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Evaluating the Impact of a Surgeon-Led Ductal Carcinoma in Situ Program on Endocrine Therapy Uptake.Annals of surgical oncology · 2026Article
- Interventions to improve oral endocrine therapy adherence in breast cancer patients.Journal of cancer survivorship : research and practice · 2025Review
- Review
- Anastrozole for the prevention of breast cancer in high-risk postmenopausal women: cost-effectiveness analysis in the UK and the USA.BMC health services research · 2024Article
- Functional and Phenotypic Characterisations of Common Syngeneic Tumour Cell Lines as Estrogen Receptor-Positive Breast Cancer Models.International journal of molecular sciences · 2023Article
- Understanding low chemoprevention uptake by women at high risk of breast cancer: findings from a qualitative inductive study of women's risk-reduction experiences.BMC women's health · 2021Article
- Cancer Chemoprevention Using Nanotechnology-Based Approaches.Frontiers in pharmacology · 2020Review
- Women's perceptions of personalized risk-based breast cancer screening and prevention: An international focus group study.Psycho-oncology · 2019Article
- Therapeutic cancer prevention: achievements and ongoing challenges - a focus on breast and colorectal cancer.Molecular oncology · 2019Review
- NRG Oncology/National Surgical Adjuvant Breast and Bowel Project Decision-Making Project-1 Results: Decision Making in Breast Cancer Risk Reduction.Cancer prevention research (Philadelphia, Pa.) · 2017Article
- Preventing invasive breast cancer using endocrine therapy.Breast (Edinburgh, Scotland) · 2017Review
- Cancer Prevention: Lessons Learned and Future Directions.Trends in cancer · 2016Review
- Physician and Patient Barriers to Breast Cancer Preventive Therapy.Current breast cancer reportsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The global cancer burden continues to rise and the war on cancer can only be won if improvements in treatment go hand in hand with therapeutic cancer prevention. Despite the availability of several efficacious agents, utilisation of preventive therapy has been poor due to various barriers, such as the lack of physician and patient awareness, fear of side effects, and licensing and indemnity issues. In this review, we discuss these barriers in detail and propose strategies to overcome them. These strategies include improving physician awareness and countering prejudices by highlighting the important differences between preventive therapy and cancer treatment. The importance of the agent-biomarker-cohort (ABC) paradigm to improve effectiveness of preventive therapy cannot be overemphasised. Future research to improve therapeutic cancer prevention needs to include improvements in the prediction of benefits and harms, and improvements in the safety profile of existing agents by experimentation with dose. We also highlight the role of drug repurposing for providing new agents as well as to address the current imbalance between therapeutic and preventive research. In order to move the field of therapeutic cancer prevention forwards, engagement with policymakers to correct research imbalance as well as to remove practical obstacles to implementation is also urgently needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.